Mechanistically, it was found that circRNA-SORE functions by binding to YBX1, and both YBX1 and circRNA-SORE can be used as biomarkers for predicting sorafenib efficacy in HCC patients. This evidence concerns the gene YBX1 and hepatocellular carcinoma.